Status:
COMPLETED
Studying the Effects of Antihypertensives on Individuals at Risk for Alzheimer's
Lead Sponsor:
University of Wisconsin, Madison
Conditions:
Alzheimer's Disease
Hypertension
Eligibility:
All Genders
40-65 years
Phase:
PHASE4
Brief Summary
Angiotensin converting enzyme inhibitors (ACE-I) are a group of blood pressure-lowering medicines. Some studies suggest that ACE-I, such as ramipril, may help prevent Alzheimer's disease (AD). The pur...
Detailed Description
High blood pressure (BP) in midlife is predictive of Alzheimer's disease (AD) in later life. Similarly, reductions in BP are associated with protection against AD. Treatment with antihypertensive medi...
Eligibility Criteria
Inclusion
- Between the ages of 40 and 65
- Mean resting blood pressure between 130-160 systolic and 85-100 diastolic
- Parent with Alzheimer's Disease
Exclusion
- Current involvement in another investigational drug trial.
- Potassium \> 5.0
- Dementia based on DSMIV criteria
- Mini-Mental State Exam (MMSE) score \< 27
- Current blood pressure medication (\< 4 months from screening)
- Weight loss medication
- Contraindications for LP
- Know diagnosis or history of hospitalization due to congestive heart failure
- Elevated creatinine (females \> 1.3 mg/dL or males \> 1.4 mg/dL at baseline)
- Diabetes Type I and II
- Know adverse reaction to an ACE-I or an angiotensin receptor blocker
- Pregnant of nursing women
Key Trial Info
Start Date :
April 9 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 26 2011
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT00980785
Start Date
April 9 2009
End Date
July 26 2011
Last Update
August 25 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wisconisn Alzheimer's Disease Research Center
Madison, Wisconsin, United States, 53705